Human antigen-specific CD4+ T cells become autoreactive after treatment with various DNA methylation inhibitors, including 5-azacytidine, procainamide, and hydralazine. This suggests a mechanism that could contribute to the development of some forms of autoimmunity. In this report we have asked whether T cells treated with DNA methylation inhibitors can induce autoimmunity. Murine CD4+ T cells were treated with 5-azacytidine or procainamide and were shown to respond to syngeneic antigen-presenting cells, similar to CD4+ human T cell clones treated with these drugs. Functional characterization demonstrated that cells treated with either drug spontaneously lysed syngeneic macrophages and secreted IL4, IL-6, and IFN--t. Adoptive transfer of 5-azacytidine-or procainamide-treated cells into unirradiated syngeneic recipients induced an immune complex glomerulonephritis and IgG anti-DNA and antihistone antibodies. These experiments demonstrate that T cells treated with either of two distinct DNA methyltransferase inhibitors are sufficient to induce a lupuslike disease. It is possible that the lysis of macrophages, together with the release of cytokines promoting B cell differentiation, contributes to the autoantibody production and immune complex deposition. These results suggest that environmental agents that inhibit DNA methylation could interact with T cells in vivo to produce a lupus-like illness, a mechanism that could have relevance to drug-induced and idiopathic lupus. (J. Clin.
Introduction
It is generally accepted that autoreactive T cells are responsible for some autoimmune diseases, but the mechanisms causing autoreactivity are controversial. Conventional models postulate that autoreactive T cells arise by failure of thymic deletion or in response to cross-reactive antigens (1) (2) (3) (4) (5) . However, recently it was reported that under certain conditions antigenspecific T cells can become autoreactive. Normally, CD4+ T cells respond to antigen presented by accessory cells such as macrophages (M4),' but are not activated by MO alone (6) .
However, if first treated with DNA methyltransferase inhibitors, antigen-specific CD4+ T cells can be activated by self determinants on autologous MO without antigen (7) (8) (9) . This autoreactivity is accompanied by changes in gene expression ( 10, 11 ) and is presumably due to altered expression ofone or more genes regulated in part by mechanisms associated with DNA methylation. Autoreactivity has been documented after treatment of cloned (7, 9) and polyclonal (8) human T cells using structurally unrelated DNA methylation inhibitors such as 5-azacytidine (5-azaC), procainamide (Pca) , and hydralazine (7) (8) (9) 12) . The reactivity to self determinants resembles an alloreactive response (7) . In mice, adoptive transfer of semiallogeneic CD4+ cells produces a chronic graft-versus-host (GvH) disease with some features of systemic lupus erythematosus (SLE) ( 13, 14) . The similarity ofthe autoreactive cells to the cells producing chronic GvH disease, together with the well-established observation that Pca and hydralazine can cause a lupus-like disease ( 15 ) , led us to propose that T cells made autoreactive with DNA methylation inhibitors might induce a disease with features of murine chronic GvH or human drug-induced lupus.
In this report, we (8) . 106 cells were then cultured with 106 irradiated (2,000 rad) C57BL/6 (Charles River) (H-2b) splenocytes in 2 ml RPMI supplemented with 10% FCS (HyClone Laboratories Inc., Logan, UT), 2 mM glutamine, 40% IL-2-containing supernatant (17) , 100 IU/ml penicillin, 100 Ag/ml streptomycin, and 5 X 10' M 2-mercaptoethanol, using flat-bottomed 24-well plates (Nunc; from Gibco Laboratories, Grand Island, NY). After 7-10 d the cells were restimulated with 0.5-1.0 x 106 irradiated C57BL/6 splenocytes and treated with 5-azaC (Sigma Chemical Co., St. Louis, MO or Aldrich Chemical Co., Milwaukee, WI) or Pca (Sigma Chemical Co.) the next day. 6 d later the cells were tested for autoreactivity or given in adoptive transfer. At this time point, staining with anti-CD4-FITC (Becton Dickinson & Co.) or anti-CD8-FITC (Coulter Corp., Hialeah, FL) followed by cytofluorography on an flow cytometer (EPICS C, Coulter Corp.) (8) demonstrated that the cells were usually 2 96% CD4'. In some experiments the cells were maintained for longer periods by restimulation with irradiated C57BL/6 splenocytes every 7-10 d. Con-A-activated T cell lines were similarly generated by culturing CD8-depleted DBA/2 splenocytes with 5 ug/ml Con A (Pharmacia LKB Biotechnology Inc., Uppsala, Sweden). These lines were also maintained in IL-2-containing media and restimulated every 7-10 d with 1 gg/ml Con A and 0.5-1.0 X 106 irradiated syngeneic splenocytes. Con A-activated lines were treated with 5-azaC 3 d after restimulation. Measurement ofT cell proliferative and cytotoxic responses. Proliferation assays were performed as described (7), using irradiated splenocytes as antigen-presenting cells (APC). To test cytotoxic responses, peritoneal MO were obtained using thioglycolate broth ( 18, 19) . This procedure routinely gives preparations containing 80-90% M4 ( 18, 19) , and morphological analysis demonstrated similar percentages in these preparations. These cells were labeled with 5'Cr and used as targets ( 11, 20) . Percent Corp.) using previously described protocols (8) . Whole blood leukocyte counts were determined using a particle counter (model ZF; Coulter Corp.) and hemoglobin concentrations were determined using the cyanmethemoglobin method and a hemoglobinometer (Coulter Corp.). Serum blood urea nitrogen (BUN) determinations were made using the urease method, and creatinine determinations using the peroxidase method, both analyzed on an Ektachem DT system (Eastman Kodak Co., Rochester, NY (22) .
Histological analysis and immunofluorescence. Tissue was prepared and stained with hematoxylin and eosin or FITC-conjugated antisera specific for IgG, IgM, IgA, and C3 (Sigma Chemical Co.) using standard procedures. Histological changes were graded using the lupus renal pathology scoring system (23) . Tissues were prepared for electron microscopy as previously described (24) (25) . Initial ELISAs for single-(ss) and double-stranded (ds) DNA ds were performed as described, with and without inhibition by purified ss-and dsDNA to confirm specificity (25) . In later studies, anti-ssDNA and anti-dsDNA were measured by coating Immulon 4 plates (Dynatech Laboratories, Inc., Chantilly, VA) with 100 ,l purified single-stranded calf thymus DNA (Sigma Chemical Co.) or purified pUC1 8 plasmid (25,ug/ml in 0.01 M PBS, pH 7.2) for 18 h at 4°C. The plates were then washed five times with PBS 0.5% Tween 20 (Sigma Chemical Co.) and then sealed with 5% BSA in PBS with 0.1% gelatin for 2 h at 23°C. The serum samples were then incubated for 18 h at 4°C, washed five times as before, then 100 Al horseradish peroxidase-conjugated goat anti-mouse heavy-and light-chain specific antisera was added at 1:2,500 final dilution (Gibco Bethesda Research Laboratories) for 2 h at 23°C. The plates were then washed five times, and were developed using o-dianisidine (Sigma Chemical Co.) as previously described (26) . OD was measured at 405 nm using a spectrometer (model Titertek Multiskan; Flow Laboratories, McLean, VA). Positive controls always included pooled NZB/W sera. A 1:100 dilution of this sera produced an OD of 0.178±0.084 (mean±SD of 12 experiments, range 0.060-0.288), which was well within the linear range of the instrument. To measure antihistone antibodies, identical assays were used, except that plates were coated with purified calf thymus histone proteins (type II-s; Sigma Chemical Co.). A 1:100 dilution of NZB/W sera produced an OD of 0.170±0.073 (mean±SD of 10 experiments, range 0.061-0.279) in these assays. Where indicated, purified ssDNA or histone proteins were added with the antisera for 30 min before adding the antisera to the well. To measure antithymocyte and antierythrocyte antibodies, antisera was incubated with DBA/2 thymocytes or erythrocytes for 30 min at 4°C, and then washed three times with PBS containing 1.0% horse serum and 0.1 % sodium azide, and then stained with GAM-FITC (Cappel Laboratories) for 30 min at 4°C. The cells were then washed three times, fixed in 1% Formalin, and then analyzed on a EPICS C or ELITE flow cytometer as described above. Determination of DNA deoxycytosine (dC) and deoxymethylcytosine (dmC) content. EL-4 cells were grown in RPMI 10% FCS supplemented with penicillin, streptomycin, and glutamine as described above. DNA was isolated and hydrolyzed to nucleosides using DNase 1, phosphodiesterase, and alkaline phosphatase as described (9) . Total dC and dmC content were determined by reverse-phase HPLC using previously described protocols (27) , and results are presented as the mean±SD of duplicate determinations.
Statistical analysis. The difference between means was compared using Student's t test. The differences between groups was tested using chi-square analysis with Yates' correction for small sample numbers or by analysis of variance, using Systat Inc. (Evanston, IL) software.
Results 5-azaC-treated murine CD4' cells respond to syngeneic APC.
Since previous experiments studied human lymphocytes, initial experiments determined if5-azaC also induced autoreactivity in murine T cells. The conalbumin-reactive cloned line D. lO.G4. 1 (H-2k) was treated with 5-azaC and then challenged with irradiated H-2k APC. Fig. 1 identical stimulation of 5-azaC-treated cells gave 18,397±338 cpm (mean±SEM above background, P < 0.001). Fig. 1 b shows a second experiment, in which the autoreactive response was inhibited by mAb to class II but not class I MHC determinants, similar to human T cells (7, 8) . In serial repeats of these experiments with various T cell lines, optimal autoreactivity was usually induced with 0.125-2.0 AM 5-azaC. The variability in optimal concentration could be attributed in part to differences between T cell lines as previously described (7).
CD4' T cells have recently been shown to lyse stimulating MO (20, (29) (30) (31) . To confirm the effect of 5-azaC, the alloreactive T cells were treated with 5-azaC and tested for syngeneic MO killing (Fig. 1 c) . Untreated cells demonstrated low-level ( 10-18%) cytolysis, which may be analagous to the syngeneic mixed lymphocyte reaction. The significance of this low level response is uncertain because adoptive transfer experiments, presented below, demonstrated no pathological effects induced by these cells. However, similar to results obtained using proliferation assays, the 5-azaC-treated cells demonstrated significantly greater killing, with a maximum at an effector/target ratio of 25:1. In two repeats of this experiment, little to no killing was seen at effector/target ratios < 5:1, and killing did not increase beyond that which occurred at an effector/target ratio of 25:1, even at ratios up to 100:1. MO lysis was inhibited by mAb to class II better than to class I MHC determinants ( Fig. 1 d) , similar to the proliferative response, and anti-LFA-1 (anti-CD 1 la) also inhibited cytotoxicity, similar to other reports (32).
Effect of 5-azaC-treated CD4' T cells in vivo.
We next examined the effect of untreated and 5-azaC-treated T cells on syngeneic hosts, using the same alloreactive CD4+ cells. Healthy, unirradiated DBA/2 mice were given one to three intravenous injections of 5 X 106 5-azaC-treated cells. Experiments in the GvH system have shown that adoptive transfer of 3-5 X 106 cells is necessary to induce GvH disease (33). Controls included age-and sex-matched DBA/2 mice given one to five injections of the same number of untreated (control) T cells or 12 weekly intravenous injections of HBSS. The results of urinalyses on these mice are shown in Table I . None of the mice receiving control cells or HBSS developed hematuria, and the majority showed zero to trace proteinuria. Rarely proteinuria of 30 mg/dl was observed in the control groups, but this was never sustained, and on repeat testing was always negative to trace. In contrast, a majority of mice receiving 5-azaCtreated cells developed significant proteinuria, defined as > 30 mg/dl present for > 2 wk, and hematuria, defined as 2 50 erythrocytes/,l on at least one occasion. The maximum proteinuria was > 100 mg/dl in the majority, and maximum hematuria was 2 250 erythrocytes/,gl. The urinary abnormalities were usually first seen 7-14 d after injection ofthe cells. Hematuria was seen between weeks 1 and 3, and lasted 7-14 d. In contrast, proteinuria of 2 30 mg/dl was more persistent, lasting up to 2 7 wk in the majority. Hematuria is somewhat unusual in murine models ofrenal disease (34, 35) , so the urinary sediment was characterized further. Fig. 2 shows photomicrographs of urine specimens from mice with active hematuria. unstimulated CD4+ splenocytes treated with 5-azaC for 3 h before adoptive transfer. These controls were performed in parallel with mice receiving three injections of proliferating, 5-azaC-treated or untreated cells (Table I ). The 5-azaC-treated, unstimulated cells were tested for autoreactivity in assays similar to those described above and did not demonstrate greater responsiveness to syngeneic APC than did untreated, unstimulated cells. None of the mice receiving heat-killed 5-azaCtreated cells, unstimulated 5-azaC-treated cells, or untreated proliferating cells developed hematuria or proteinuria. In contrast, all mice receiving three injections of viable 5-azaCtreated, proliferating cells developed active urinary sediments. These results suggest that viable, proliferating, 5-azaC-treated T cells are required to produce the urinary abnormalities, and that activation or 5-azaC-treated alone is not sufficient. Histological studies were performed on 10 mice given one to five injections of control cells and 14 mice given one to five injections of 5-azaC-treated cells (Fig. 3 ). Histological analysis was usually performed 2 wk after the last injection of cells. All mice that received treated cells and developed abnormal urinalyses had evidence for a proliferative glomerulonephritis. The glomerular alterations included variable mesangial proliferation, increased matrix deposition, and variable neutrophilic infiltration (see also Figs. 9 and 10). Some focal scarring and fibrosis was observed in mice receiving multiple injections of 5-azaC-treated cells. Using the lupus renal pathology scoring system (21 ), the activity index was 3-4+ and chronicity index was 2-3+. In contrast, none ofthe mice that received untreated cells developed abnormal renal histology. Additional studies were performed on three mice receiving heat-killed, 5-azaCtreated cells and three mice receiving unstimulated, 5-azaCtreated cells. No histological abnormalities were observed in mice receiving these control injections.
Immunofluorescence was performed on kidney sections from four mice given 5-azaC-treated cells and four mice given untreated T cells. Each group received injections at week 0 and 2 and were killed at week 4. The mice receiving 5-azaC-treated cells had active hematuria but the mice receiving untreated cells did not. The mice that received 5-azaC-treated T cells had significantly greater glomerular IgM, IgG, and IgA deposition than did control mice (Fig. 4) . C3 deposition was also seen in glomeruli from mice receiving 5-azaC-treated but not untreated cells (data not shown). The immunoglobulin and complement deposition was mesangial in distribution. In addition, IgG deposition was seen at the dermal-epidermal junction, resembling a lupus band test (Fig. 5) 1.14±0.025 mg/ml, untreated vs. 5-azaC-treated) between the groups receiving the Con A-activated cells. Fig. 7 shows the results ofthe ELISAs for IgG antibodies to ssDNA as well as to histones. Mice receiving 5-azaC-treated cells (numbers 1-5) developed significantly greater amounts ofanti-ssDNA and antihistone antibodies than mice receiving untreated cells (P < 0.001 for each). Lesser amounts of antihistone antibodies were produced than anti-ssDNA antibodies relative to controls of pooled sera from female NZB/W mice (P < 0.01). Since total IgG concentrations were the same in both groups, in these experiments protein concentrations were not normalized. To confirm specificity, purified ssDNA or histone protein was added to the respective ELISAs. The ELISAs for anti-ssDNA and histone antibodies were significantly inhibited (P < 0.001 for each). It is noted that the titers obtained in this experiment were significantly less than the NZB/W controls, whereas the titers shown in Fig. 6 approximate the titer of controls. This could be due to a difference in titer between the pooled NZB/ 10 and 100 tuM Pca was 4.38±0.01 and 4.35±0.01% (P = 0.003). This represents a decrease of 0.26% or -160,000 methylated bases (36) . Similar to our previous report (37) , the decrease caused by tiM Pca was smaller and not statistically significant. Controls in which EL-4 cells were treated with 0.25 tM 5-azaC demonstrated a 0.30% decrease in overall dmC content.
The effects of Pca and 5-azaC on murine T cells were then compared. CD4', alloreactive DBA/2 anti-C57BL/6 T cells were treated with 5-50 tiM Pca and 6 d later were tested for reactivity to syngeneic and allogeneic APC. Fig. 8 a compares the proliferative response of treated and untreated T cells to syngeneic APC. In this figure, the autoreactive response is expressed relative to the response to the same number of allogeneic APC. Significant autoreactivity (P < 0.01) is seen at all concentrations tested, similar to the results observed in cloned human T cells (9, 37) . Fig. 8 Fig. 1 . Pca-treated cells demonstrated significantly (P < 0.01) greater killing, which was inhibited with anti-CD 1 la and anti-Iad but not anti-Iak antibodies. In the experiment shown, complete inhibition was not achieved using the anti-Iad mAb. However, a second experiment performed under identical conditions gave complete (0±0.7%) inhibition. The variability in the results may be attributed to the normalization of the data to the spontaneous 5"Cr release from the Mo. These mAb inhibition results are also similar to those shown in Fig. 1 .
5-azacytidine has recently been reported to increase CD 11 a expression on the surface ofhuman T cells, which may contribute to the development of autoreactivity by stabilizing the low affinity interaction between the T cell receptor and Ia determinants. This increase could not be attributed to DNA synthesis inhibition and was presumably due to inhibition ofDNA methylation ( 11) . Subsequent studies have shown that Pca causes an identical increase in CD 1 a expression without affecting DNA synthesis (reference 38; K. S. O'Rourke, D. Power, and B. C. Richardson, manuscript in preparation). Therefore it was important to determine if a similar effect was induced by 5-azaC and Pca in murine T cells. In Fig. 8 c, the alloreactive CD4' T cell line was treated with 5-azaC or Pca, and 6 d later CD 1 a expression was compared on treated and untreated cells. The peak CD 1 a immunofluorescence of the untreated cells was 4. In contrast, the peak immunofluorescence was 65 in the 5-azaC-treated cells. The Pca-treated cells demonstrated two peaks, one at -10 and one at 65. This suggests that both Pca and 5-azaC can induce a > 10-fold increase in CDlI a expression on a subset ofthe cells, similar to that seen in human T cells ( I1 ). To test whether altered cell cycle kinetics contribute to increased LFA-1 expression in murine cells, the alloreactive T cell lines were treated for 6 d with 100 ,uM hydroxyurea, and then LFA-1 expression and cell cycle kinetics were compared between treated and untreated cells. Using propidium iodide fluorescence to examine cellular DNA content, hydroxyurea was found to decrease the percent of cells in S and G2M compared with untreated controls (71±1:25±1:5±1 vs 83±1:14 ± 1:3±0.1, GoGI :S:G2M in untreated vs. treated, mean±SD of duplicate determinations). However, LFA-1 expression decreased by 40% on the treated cells, arguing against an effect of DNA synthesis inhibition on increased LFA-1 expression. In addition, concentrations of 5-azaC that increased LFA-1 expression had no significant effect on murine T cell cycle kinetics (74±3:17+5:8+2, GoG,:S:G2M).
Since human CD4+ T cells treated with 5-azaC and Pca secrete cytokines capable of promoting B cell differentiation into antibody-secreting cells (8) , the effects of 5-azaC and Pca on CD4+ T cell cytokine secretion were compared. (Fig. 9) and 5-azaC-treated proliferating cells again demonstrated hypercellular glomeruli with increased mesangial matrix, identical to that previously shown (Fig. 3) , and immunofluorescence again demonstrated increased glomerular IgG deposition rela- tive to controls, identical to that shown in Fig. 4 (data not shown). Fig. 10 shows electron micrographic pictures of glomeruli from mice receiving untreated and Pca-treated T cells. Mesangial electron-dense immune deposits, neutrophils, and endothelial cell disruption with fibrin deposition are seen in glomeruli from mice receiving Pca-treated, but not untreated, cells. Identical changes were observed in glomeruli from mice receiving 5-azaC-treated cells (data not shown).
Sera were then tested for total IgG concentration and IgG antihistone and anti-ssDNA antibodies and compared with the same pooled NZB/W sera used in Fig. 7 . DBA/2 mice receiving untreated alloreactive T cells had 0.98±0.1 mg/ml IgG, and mice receiving unstimulated, Pca-treated T cells had 1.00±0.09 mg/ml. Mice receiving 5-azaC-treated alloreactive cells had 1.10±0.07 mg/ml, and mice receiving Pca-treated alloreactive cells had 1.1 1±0.1 mg/ml IgG (mean±SEM ofthe four or frve mice in each group). These differences were not significant (P > 0.05) and approximate those of normal mice (35) . Fig. 11 compares the titer and specificity of IgG antissDNA and antihistone antibodies in mice receiving Pca-and 5-azaC-treated alloreactive cells. Fig. 11 a demonstrates that mice receiving Pca-or 5-azaC-treated, activated cells develop significantly (P < 0.01 and P < 0.02, respectively, relative to mice receiving untreated, activated cells) greater amounts of anti-ssDNA antibodies than controls. In this experiment the titers approximate those of the NZB/W controls and are greater than those found using the Con A-activated cells. This is most likely due to the longer duration of this experiment (6 vs. 4 mo), because earlier bleedings from this group of mice demonstrated lower anti-ssDNA titers (data not shown). Fig.  11 b shows that the mice receiving Pca-( 176±50%, P < 0.02) or 5-azaC-(46±7%, P < 0.05) treated cells develop more antihistone antibodies than controls (26±0.4% for stimulated untreated and 9±3% for unstimulated, Pca treated). Interestingly, mice receiving Pca-treated cells made greater amounts of antihistone antibody than mice receiving 5-azaC-treated cells (P < 0.05). The reason for this is not apparent, but is reminescent of the specificity of autoantibodies in humans receiving longterm Pca therapy (39) . Fig. 11 c compares the anti-ssDNA titer of sera from representative mice receiving Pca-or 5-azaC-treated cells with pooled sera from female NZB/W mice and demonstrates that the titers are comparable. Fig. 11 d demonstrates that the titers of antihistone antibodies from representative mice receiving Pca-treated cells are comparable to titers from NZB/W mice, whereas mice receiving 5-azaC-treated cells appear to make relatively less antihistone antibodies, confirming the results shown in Fig. 11 b. Control sera from mice receiving Pca- There is normal cellularity, no increase in mesangial matrix, and no evidence of neutrophils. X400. treated, unstimulated cells were also studied at dilutions of 1:100 and 1:300. At a dilution of 1:300, the OD of the antissDNA assay was 0.021±0.009 (mean ± SD of the ODs from the five mice, each performed in duplicate) above background, and the average OD of the antihistone assays was less than background. In contrast, in this assay, a 1:100 dilution of NZB/W sera gave ODs of 0.134±0.006 and 0.1 19±0.004 in the anti-ssDNA and antihistone ELISAs, respectively, and serial dilutions ofthe NZB/W sera only reached levels comparable to 1:300 dilutions ofthe control sera at dilutions of 1:1,600-1:3,200. Fig. 1 1, e and fdemonstrate that purified ligands inhibit the ELISAs, confirming specificity. In Fig. 11 e it may be seen that complete inhibition was not achieved using sera from a mouse receiving Pca-treated cells. This may be due to higher titers of antibody in this animal, since 5 ,gg ofpurified ssDNA gave 74% inhibition in a second animal from this group.
In additional experiments, evidence for antithymocyte and antierythrocyte antibodies was sought, similar to those reported in chronic GvH disease ( 14) . However, again using female NZB/W sera as a positive control (35 ) and flow cytometry to test for Ig binding, no evidence for significant amounts of antithymocyte or antierythrocyte antibodies were found. IgG anti-dsDNA antibodies were also sought, and evidence for small amounts were found in mice receiving Pca-treated cells (OD 0.016±0.002 vs. 0.028±0.005, untreated vs. Pca-treated, P < 0.05). However, the titer of these antibodies was < 25% that of pooled sera from NZB/W mice, and the significance of this low titer autoantibody is uncertain.
Discussion
The goal ofthese studies was to determine ifT cells treated with DNA methyltransferase inhibitors could induce an autoimmune disease. The results demonstrate that activated, syngeneic CD4+ T cells treated in vitro with either 5-azaC or Pca are sufficient to induce glomerulonephritis and anti-ssDNA and antihistone antibodies in unirradiated DBA/2 mice, a strain that does not normally develop autoimmune diseases. To the best ofour knowledge, this is the first description ofan autoimmune disease being induced by T cells treated in vitro with either of these agents.
Initial experiments asked whether autoimmunity could be induced using the well-characterized DNA methylation inhibitor 5-azaC. Adoptive transfer of CD4', proliferating cells treated with this drug induced hematuria, proteinuria, cellular urinary casts, mesangial immune complex deposition, a proliferative glomerulonephritis, IgG deposition at the dermal-epi- 48 Quddus, Johnson, Gavalchin, Amento, Chrisp, Yung, and Richardson ."a 4'. ..:
;1 Figure 10 . Electron microscopic analyses of glomeruli from mice receiving Pca-treated T cells. A illustrates normal glomerular ultrastructure, which was found in kidneys from animals receiving untreated T cells as described in Fig. 9 14) , suggesting that in some fashion alloreactive CD4+ T cells, used in the initial studies, may be unique in the ability to induce autoimmunity. Therefore CD4+ T cells activated with Con A were similarly treated with 5-azaC and injected into syngeneic recipients. Identical results were found. This demonstrates that cells capable ofinducing renal disease and autoantibodies after 5-azaC-treated can be found in CD4+ T cell lines activated by either stimulus. Again, it is possible that a specific CD4+ T cell subset, defined by cytokine secretion or by antigenic specificity, is required and present in both lines. Future studies will examine this possibility.
5-azaC could cause the autoimmunity by altering gene expression in proliferating T cells, but it is also possible that inadvertent coadministration of 5-azaC with the transferred cells contributes to the in vivo abnormalities. However, transfer of 5-azaC as a mechanism seems unlikely because the cells were treated 6 d before adoptive transfer and 5-azaC is unstable in aqueous media (42) . Furthermore, the cells were thoroughly washed before transfer. Finally, heat-killed 5-azaC-treated cells and unstimulated, 5-azaC-treated cells failed to induce autoantibodies or renal disease. For these reasons, the disease is most likely due to an effect of 5-azaC on T cells, rather than carryover of the drug.
At the concentrations used, the major effect of 5-azaC is hypomethylation of newly synthesized DNA (43, 44) . DNA methylation is one of the mechanisms regulating gene expression (45) , and in many systems hypomethylation ofregulatory sequences has been shown to correlate with increased gene transcription (45) . By inhibiting DNA methylation, 5-azaC can alter gene expression (46) . It seems reasonable to postulate that changes in DNA methylation are responsible for the increased CD 1 a expression observed in this and other studies (1 1, 38 ) and that the autoreactivity induced is also due to altered gene expression. This would explain why treatment of proliferating cells is required to produce the increase in LFA-1, autoreactivity, and autoimmune disease reported in this and other studies (7, 8, 1 1 ).
To further examine whether DNA methylation inhibition could be responsible for the autoimmunity, the effects of 5-azaC and Pca were compared. Pca was shown to decrease T cell dmC content, increase CD Ila expression, and induce autoreactivity in murine T cells, suggesting that 5-azaC and Pca have identical effects on proliferating murine as well as human T cells at the DNA, protein, and functional levels. It should be noted that these murine studies differ from the human studies in that polyclonal cells were used in most ofthe murine experiments. This makes it difficult to exclude the possibility that the increased CD 1 a expression and the autoreactivity induced could result from selection of T cell subsets. However, the previous results demonstrating identical effects on cloned human T cells and the present demonstration that cloned murine T cells also become autoreactive after 5-azaC-treated suggests that the changes observed are due to alterations in the treated cells rather than subset selection. (27) , increased LFA-1 expression ( 1), and a subset that appears to be autoreactive ( 11), suggesting that a similar mechanism may be involved in idiopathic human SLE.
The mechanism by the which treated cells might induce autoimmunity was also explored. The chronic GvH model demonstrates that semiallogeneic CD4 + cells responding to self determinants on host APC can induce anti-DNA antibodies, antihistone antibodies, and immune complex renal disease ( 13, 14). 5-azaC-and Pca-treated human CD4+ T cells were previously shown to respond to selfdeterminants on MO (7) (8) (9) and, in this report, 5-azaC-and Pca-treated murine CD4+ cells were also shown to respond to syngeneic APC. Since this autoreactive response to syngeneic APC resembles that of semiallogeneic T cells to host APC in the chronic GvH model, it seems reasonable to propose that this autoreactive response could contribute to the autoimmune disease induced by these cells. The effects of the autoreactive cells on syngeneic MO and the pattern of cytokines secreted by the treated cells were therefore examined to learn how the autoreactive cells might induce autoimmunity.
MO killing was observed using 5-azaC-and Pca-treated cells. The MO death could result from specific killing or the nonspecific release of cytotoxic molecules by cultured T cells. However, the cytotoxic responses were inhibited with mAb to class II MHC determinants as well as LFA-1, arguing against nonspecific cytotoxicity and supporting a mechanism requiring cell-cell contact similar to the Ia-dependent APC killing frequently caused by CD4' T cells (48, 49 Pca-treated alloreactive cells (Pca, n = 4), or 5-azaC-treated alloreactive cells (5-azaC, n = 5) were tested for IgG anti-ssDNA antibodies as described in Fig. 7 . Results are expressed relative to a standard curve of pooled NZB/W sera as before and represent the mean of duplicate de- terminations. The filled rectangle with error bars represents the mean±SEM of the data points in each column. (b) The same sera were tested for IgG antihistone antibodies, using the methods described in a. The secretion of IL-4, IL-6, and IFN-'y could contribute to the development of autoimmunity. Numerous reports document the ability of these cytokines to promote B cell antibody synthesis (for review see reference 54). In addition, each of these cytokines has been implicated in the pathogenesis of lupus (55-57). It is possible that secretion ofthese cytokines in lymph nodes, together with intracellular antigens released by lysed MO, could promote autoantibody synthesis and secretion by adjacent B cells. Since previous experiments demonstrated that cytokines secreted by similar autoreactive CD4+ cells could promote polyclonal B cell activation (8) , and other murine models of lupus have significant polyclonal B cell activation and hypergammaglobulinemia (35) , it is somewhat surprising that mice receiving the drug-treated cells did not also develop hypergammaglobulinemia. This may be due to the transient nature of the drug-induced autoreactivity (7) and is consistant with the relatively mild disease induced. An alternative explanation for how the treated cells induce autoimmunity is that the host mounted an immune response to novel determinants present on the treated cells and this response in some fashion contributed to the disease. This seems unlikely, since heat-killed, 5-azaC-treated cells failed to induce renal disease and autoantibodies. However, it remains possible that a heat labile determinant on the cells was destroyed by this treatment. Proof that the autoreactive response contributes to the disease will require selectively reversing the autoreactivity, perhaps by using mAbs specific for those molecules important to or responsible for the autoreactive response.
In contrast to the lupus-like disease described in this report, Yoshida et al. (58) reported that parenteral 5-azaC diminishes the massive lymphadenopathy and the lupus-like syndrome that spontaneously develop in MRL/lpr mice. This suggests an apparent contradiction. However, Yoshida et al. found no inhibitory effect of 5-azaC on BXSB mice, another strain spontaneously developing lupus. It is likely, as Yoshida et al. point out, that the beneficial effect of 5-azaC in MRL/lpr mice may be due to the inhibition of the massive lymphoproliferation that occurs in this strain (58) . This is consistent with the known inhibitory effect of 5-azaC on DNA synthesis (59) .
In summary, these experiments support the hypothesis that T cells made autoreactive with DNA methylation inhibitors can induce a lupus-like autoimmune disease. Since agents such as Pca, hydralazine, and ultraviolet light inhibit DNA methylation and induce T cell autoreactivity (9, 38, 60 ; and manuscript in preparation), and patients with idiopathic lupus have T cells with hypomethylated DNA (27) , it is possible that similar mechanisms are involved in 5-azaC-induced murine lupus, in human drug-induced lupus, and some forms of idiopathic SLE.
